Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy
NCT: NCT07531927 · RECRUITING
Brief Summary
Geographic atrophy (GA) is a progressive eye disease that causes the degeneration of the retinal cells, particularly in the macula, leading to vision loss. The goal of this pilot study is to evaluate the safety and the effectiveness of transcorneal electrical stimulation (TES) therapy with the OkuStim 2 System in patients with geographic atrophy (GA). Researchers will compare the effects of two different electrical stimuli with a placebo to see if the stimuli are safe and can slow down the progression of the disease. Participants will be randomly assigned to one of these three groups: * TES-treatment with a rectangular stimulus * TES-treatment with a repetitive ramp stimulus * Placebo (sham) treatment Participants will apply the therapy at home, once a week for 30 minutes each over a duration of 1 year.
Frequently Asked Questions
What is Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy?
Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy is a clinical trial registered under NCT07531927. Current status: RECRUITING.
What is the status of NCT07531927?
The current status of NCT07531927 (Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy) is: RECRUITING.
When did Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy start?
Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy started on 2026-05-05.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.